May 10 (Reuters) - Cameron Health Inc, which agreed in March to be acquired by Boston Scientific Corp, said on Thursday it s implantable heart defibrillator proved safe and effective for treating patients at risk for sudden cardiac arrest in a 330-patient clinical trial.
Cameron's implantable cardioverter defibrillator (ICD) is the first such device that does not use intravenous leads, or electric wires, to transmit electricity from the device to the heart. Le ads are often the weak link of the defibrillator system and can cause serious complications.
"Conventional ICDs are a proven therapy with a long clinical track record; however, complications related to transvenous leads, or wires placed in the heart, can be quite serious for patients," said Dr Martin Burke, Professor of Medicine and Director of the Heart Rhythm Center at the University of Chicago.
"We did not observe the typical lead-related complications with the S-ICD System, so having an alternative treatment for patients that can virtually eliminate transvenous lead complications is an important step forward for ICD therapy," he said.
Results of the study were presented at the Heart Rhythm Society's Annual Scientific Sessions in Boston.